Results 311 to 318 of about 38,942 (318)

Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

Ophthalmology, 2014
Allen C Ho
exaly  

Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Ophthalmology, 2011
Michael J Elman, Jennifer K Sun
exaly  

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2019
Peter A Campochiaro, Carl Regillo, Giulio Barteselli   +2 more
exaly  

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

Angiogenesis, 2012
exaly  

Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

Ophthalmology, 2010
Quan Dong Nguyen, Thomas A Ciulla
exaly  

Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study

Ophthalmology, 2011
Peter A Campochiaro, Allen C Ho
exaly  

Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema

Ophthalmology, 2014
Ursula M Schmidt-Erfurth, Frank G Holz, Paolo Lanzetta   +2 more
exaly  

Ranibizumab Regimen Favorable in nAMD

Internal Medicine News, 2010
openaire   +2 more sources